See JNCCN.org for supplemental online content.
Dr. Kurzrock has consultant fees from Sequenom and an ownership interest in RScueRx Inc. Dr. Kurzrock receives research funding from Merck, Serono, Genentech, Pfizer, Foundation Medicine, Inc., Sequenom and Guardant Inc. Dr. Olszanski participated in advisory boards for Takeda Oncology, Bristol-Myers Squibb, Merck & Co., Inc., and Celgene Corporation. Dr. Ettinger has served on a data safety monitoring board for ARIAD Pharmaceuticals, Inc. and as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., Eisai Inc., Golden Biotechnology Corp., Helsinn Therapeutics (U.S.), Inc., Eli Lilly and Company, Genentech, and Sandoz, Inc. Dr. Schwartzberg has a consulting agreement with Caris Life Sciences. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
EngstromPFBloomMGDemetriGD. NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement. J Natl Compr Canc Netw2011;9:S1–15.
TsimberidouAMIskanderNGHongDS. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res2012;18:6373–6383.
Fontes JardimDLSchwaederleMWeiC. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst2015;107. pii: djv253. doi: 10.1093/jnci/djv253.
SchwaederleMZhaoMLeeJJ. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials[published online ahead of print August 24 2015]. J Clin Oncolpii: JCO.2015.61.5997.
WetterstrandKA. DNA sequencing costs: data from the NHGRI Genome Sequencing Program (GSP). Available at: http://www.genome.gov/sequencingcosts/. Accessed January 29 2015.
JohnsonD. ASCO attendees anticipate increasing use of molecular diagnostics over next decade. Available at: http://www.obroncology.com/blog/2015/07/asco-attendees-anticipate-increasing-use-of-molecular-diagnostics-over-next-decade/. Accessed September 2 2015.
VidwansSJTurskiMLJankuF. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience2014;1:614–623.
TsimberidouAMRingborgUSchilskyRL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Ed Book2013;118–125.
WhelerJLeeJJKurzrockR. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res2014;74:7181–7184.
VenookAPArcilaMEBensonABIII. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw2014;12:S1–21.
NCI Molecular Analysis for Therapy Choice Program (MATCH) & Pediatric MATCH. National Cancer Institute Web site. Available at: http://www.cancer.gov/clinicaltrials/noteworthy-trials/match. Accessed February 3 2015.
Lung-MAP launches: first precision medicine trial from National Clinical Trials Network. National Cancer Institute Web site. Available at: http://www.cancer.gov/newscenter/newsfromnci/2014/LungMAPlaunch. Accessed February 3 2015.
HeuckmannJMThomasRK. A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. Ann Oncol2015;26:1830–1837.
RodonJSoriaJCBergerR. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) consortium trial. Ann Oncol2015;26:1791–1798.
SchwaederleMDanielsGAPiccioniDE. On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol Cancer Ther2015;14:1488–1494.